M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma
Michele Cavo,Paola Tacchetti,Francesca Patriarca,Maria Teresa Petrucci,Lucia Pantani,Michela Ceccolini,Monica Galli,Francesco Di Raimondo,Claudia Crippa,Elena Zamagni,Patrizia Tosi,Franco Narni,Sara Bringhen,Vittorio Montefusco,Massimo Offidani,Silvia Buttignol,Anna Levi,Ausilia Gorgone,Annamaria Brioli,Maria Caterina Pallotti,Tonino Spadano,Norbert Pescosta,Luca Baldini,Antonio Ledda,Tommaso Caravita,Antonietta Falcone,Alfonso Zaccaria,Giulia Perrone,Alessandro Petrucci,Antonio Palumbo,Mario Boccadoro,Michele Baccarani +31 more
TL;DR: In comparison with TD, VTD effected significantly higher rates of response (≥partial response: 78.5% vs 92%, P), and the rate of complete response (CR)/near CR (nCR) following three 21-d cycles of induction therapy.
Journal ArticleDOI
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
Antonio Palumbo,Alessandra Bertola,Pellegrino Musto,Tommaso Caravita,Vincenzo Callea,Martina Nunzi,Mariella Grasso,Patrizia Falco,Clotilde Cangialosi,Mario Boccadoro +9 more
TL;DR: Thalidomide is an immunomodulatory drug with strong antimyeloma activity that is an effective treatment for multiple myeloma at disease recurrence and at diagnosis, both as a single agent and in combination with steroids or chemotherapy.
Journal ArticleDOI
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto,Sara Bringhen,Massimo Offidani,Giulia Benevolo,Francesca Patriarca,Roberto Mina,Antonietta Falcone,Lorenzo De Paoli,Giuseppe Pietrantuono,Silvia Gentili,Caterina Musolino,Nicola Giuliani,Annalisa Bernardini,Concetta Conticello,Stefano Pulini,Giovannino Ciccone,Vladimir Maisnar,Marina Ruggeri,Renato Zambello,Tommasina Guglielmelli,Antonio Ledda,Anna Marina Liberati,Vittorio Montefusco,Roman Hájek,Mario Boccadoro,Antonio Palumbo +25 more
TL;DR: In the overall population, the alkylator-containing triplets MPR and CPR were not superior to the alKYlator-free doublet Rd, which was associated with lower toxicity.
Journal ArticleDOI
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers,Laurent Garderet,K. Martin Kortüm,Michael O'Dwyer,Niels W.C.J. van de Donk,Mascha Binder,Sandra Maria Dold,Jill Corre,Yves Beguin,Heinz Ludwig,Alessandra Larocca,Christoph Driessen,Meletios A. Dimopoulos,Mario Boccadoro,Martin Gramatzki,Sonja Zweegman,Hermann Einsele,Michele Cavo,Hartmut Goldschmidt,Pieter Sonneveld,Michel Delforge,Holger W. Auner,Evangelos Terpos,Monika Engelhardt +23 more
TL;DR: The European Myeloma Network group updated their guidelines on different diagnostic recommendations, which should be of value to enable appropriate use of the recommendations both at diagnosis and during follow-up.
Journal ArticleDOI
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Alessandra Larocca,Sandra Maria Dold,Sonja Zweegman,Evangelos Terpos,Ralph Wäsch,Mattia D'Agostino,Sophia Scheubeck,Hartmut Goldschmidt,Michele Cavo,Heinz Ludwig,Christian Straka,Sara Bringhen,Holger W. Auner,Jo Caers,Martin Gramatzki,Massimo Offidani,Meletios A. Dimopoulos,Hermann Einsele,Mario Boccadoro,Pieter Sonneveld,Monika Engelhardt +20 more
TL;DR: Second-generation novel agents have also been evaluated as salvage therapy in the elderly, and these new agents certainly represent a further step forward in the treatment armamentarium for elderly patients with multiple myeloma.